SLC1A5/ASCT2 Antibody

About the Target

SLC1A5/ASCT2 is a target of interest in many antibody-based workflows. SLC1A5, also known as ASCT2 (Alanine-Serine-Cysteine Transporter 2), is a sodium-dependent neutral amino acid antiporter that plays a crucial role in transporting glutamine, a vital amino acid for rapidly proliferating cells, including those in cancer. ASCT2 belongs to the solute carrier family 1 (SLC1) and features transport and scaffold domains linked by a key ECL2a loop that facilitates conformational changes during the transport cycle. Depending on the literature source, SLC1A5/ASCT2 may also be discussed as SLC1A5/ASCT2 and ASCT2.

Reported cellular context includes cell membrane and membrane, which can matter when signal is compared across treatments or changing cell states. Following SLC1A5/ASCT2 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

SLC1A5/ASCT2 is commonly interpreted in the context of cancer, metabolism, and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell membrane and membrane, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cell membrane and membrane across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• responses linked to nutrient status, mitochondrial state, or metabolic rewiring
• signal-dependent shifts after ligand, inhibitor, or growth-factor perturbation

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for SLC1A5/ASCT2. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in SLC1A5/ASCT2 reflect biology rather than handling. When interpreting SLC1A5/ASCT2, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep SLC1A5/ASCT2 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.